
New Launch16 Nov 2026, 08:41 am
Glenmark Pharma USA launches authorized generic of INLYTA
AI Summary
Glenmark Pharmaceuticals Inc., USA has launched an authorized generic version of INLYTA (axitinib) tablets, 1 mg and 5 mg. This launch aims to increase access to affordable medicines in the United States. INLYTA had U.S. annual sales of approximately $538.4 million for the 12 months ending September 2026, according to IQVIA data. This move aligns with Glenmark's strategy to expand its portfolio and address patient needs in oncology.
Key Highlights
- Glenmark USA launches authorized generic of INLYTA (axitinib) tablets.
- Aims to provide affordable access to cancer medication in the US.
- INLYTA had US sales of ~$538.4 million in the 12 months ending Sep 2026.
- Strengthens Glenmark's oncology portfolio in the US market.
Price Impact
More from GLENMARK